elliquence Names Bill Pfost as Chief Executive Officer

BALDWIN, N.Y., Oct. 8, 2026 /CourierPR/ -- elliquence, a global leader in minimally invasive surgical technologies, has appointed Bill Pfost as its new Chief Executive Officer. Pfost brings over three decades of experience in the spine industry, having held executive roles at companies such as Zimmer Spine, Paradigm Spine, and American Medical Concepts. His appointment comes as elliquence aims to expand its presence in the U.S. and global markets, particularly in the adoption of minimally invasive endoscopic spine solutions.

Pfost's career highlights include his role as Chief Revenue Officer at Companion Spine, where he drove the company's vision as a leader in posterior dynamic stabilization. His earlier career at U.S. Surgical Corporation was marked by his involvement in driving the adoption of laparoscopic cholecystectomy, a minimally invasive surgical technique that transformed general surgery. Prior to his current role, Pfost also served as Chief Commercial Officer at Medtronic Spine, where he played a key role in the development and commercialization of advanced spinal technologies.

elliquence, based in New York, is known for its Surgi-Max Ultra radiofrequency platform and Trigger-Flex bipolar systems, which provide unparalleled precision in soft tissue management and preservation. The company's mission is to partner with the medical community to develop high-quality, cost-effective solutions that enhance patient outcomes while reducing procedural risks and recovery times. With Pfost at the helm, elliquence aims to continue its mission of improving the efficiency and effectiveness of minimally invasive procedures, while maintaining its commitment to innovation and patient care.

The appointment of Pfost is part of elliquence's broader strategy to expand its market presence and accelerate the adoption of minimally invasive endoscopic spine solutions. The company continues to build awareness of these techniques as an important option across a range of spine conditions and procedures. By enabling physicians to access and treat targeted anatomy with minimal disruption to surrounding healthy tissue, endoscopic interventions may offer appropriately selected patients reduced recovery times and the potential for same-day outpatient treatment. This approach reflects elliquence's longstanding philosophy that, when clinically appropriate, less intervention can deliver meaningful benefits for both physicians and patients.

With Pfost's appointment, elliquence is poised to further its leadership in the minimally invasive surgical technologies market. The company's commitment to innovation and patient care, combined with Pfost's extensive industry experience, positions elliquence to continue its growth and impact in the spine care sector.